Pharma Tech

Biohaven partners with Ono in $100m IgG degrader deal

Oct 9, 2026, 8:00 AM

Read Full Article → Biohaven partners with Ono in $100m IgG degrader deal

Translate article text

Choose a language and wait for the translated text.

Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio.